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The data presented in this article are related to the research article
entitled “The autoimmune risk gene ZMIZ1 is a vitamin D
responsived marker of a molecular phenotype of multiple sclero-
sis” Fewings et al. (2017) [1]. Here we identify the set of genes
correlated with ZMIZ1 in multiple cohorts, provide phenotypic
details on those cohorts, and identify the genes negatively corre-
lated with ZMIZ1 and the cells predominantly expressing those
genes. We identify the metabolic pathways in which the molecular
phenotype genes are over-represented. Finally, we present the
flow cytometry gating strategy we have used to identify the
immune cells from blood which are producing ZMIZ1 and RPS6.ier Inc. This is an open access article under the CC BY license
/j.jaut.2016.12.006
R. Booth).
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N. Fewings et al. / Data in Brief 11 (2017) 364–370 365& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Biology
ore specific subject area Autoimmune Genetics
ype of data Tables, Figures
ow data was acquired Molecular phenotypes are determined from transcriptomic data
(RNAseq, Microarray) derived from previously published sources
[2–4]
Molecular pathways were analysed using GeneGo, Metacore.
Flow Cytometry data was acquired using Canto II (BD Biosciences)
and Fortessa (BD Biosciences) instruments.ata format Analyzed
xperimental factors Samples are from whole blood collected in to PAXgene tubes for RNA
analysis. The source of samples were healthy controls and Multiple
Sclerosis patients not on therapy from Australia and the United States.xperimental features Gene expression in whole blood was interrogated by transcriptomic
and RTPCR procedures to identify genes dysregulated in MS and
correlated gene sets (mRNA level). Flow cytometry was used to
identify immune cell subsets in which ZMIZ1 and RPS6 were most
highly expressed (protein level).ata source location Cohorts of MS patients and controls are from Sydney and Perth in
Australia; and Miami and San Francisco in United States.ata accessibility UCSF CIS Cohort Transcriptome Source Data is in Repository
GSE41846 (url: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc¼GSE41846)
ANZgene Transcriptome Source Data is in Repository GSE17048 (url:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE17048)Value of the data
1. The detailed list of genes defining the ZMIZ1 molecular phenotype in multiple cohorts is described
(Supplementary Table 1).
2. The cohorts used to identify the genes in the ZMIZ1 molecular phenotype (Table 1).
3. The genes negatively correlated with ZMIZ1 expression in whole blood and the immune cells in
which they are expressed are identified (Fig. 1).
4. The gene pathways indicated as overrepresented with the genes of the ZMIZ1 molecular pheno-
type are identified (Fig. 2).
5. The flow cytometry gating strategy used to identify the immune cells most highly expressing
ZMIZ1 and RPS6 are diagrammed (Fig. 3).
6. A list of Multiple Sclerosis (MS) risk SNPs tested for association with gene expression in whole
blood in the study published in [1] (Table 2).1. Data
We have recently described a gene, ZMIZ1, whose expression is dysregulated in the blood of
people with MS [1]. From transcriptomic data, the expression of this gene is tightly correlated with
Table 1
Usage and source of various cohorts in this work.
Cohort Name Used in this study in: Numbers of individuals Original Reference
Sydney PCR cohort Figures 2, 3, 4, 5, 6, 7, 9 n¼39 untreated MS
n¼40 healthy controls
[1]
Miami cohort Figures 3, 6, 7 n¼73 untreated MS
n¼32 healthy controls
[1]
Treated MS cohort Figure 10 Total, n¼78:
n¼10, glatiramer acetate
n¼18, fingolimod
n¼20, interferon beta
n¼23, natalizumab
n¼7, dimethyl fumarate
[8]
ANZgene (microarray) cohort Figures 1B, 6, 7 n¼99 untreated MS;
n¼45 healthy controls
[2]
Sydney RNASeq cohort Figures 1, 3, 6, 7, Supplementary
Figure. 1 and 2
n¼32 untreated MS;
n¼40 healthy controls
[4]
CIS cohort Figure 1B n¼42 CIS [3]
N. Fewings et al. / Data in Brief 11 (2017) 364–370366that of many others. The set of genes whose expression is most correlated with ZMIZ1 across cohorts
from Australia and the United States is defined in Supplementary Table 1. The cohort details are
described in Table 1. The genes whose expression is most positively correlated with that of ZMIZ1 is
previously described [1]. The genes most negatively correlated with ZMIZ1, and the immune cell
subsets in which they are predominantly produced, are shown in Fig. 1. Gene pathway analysis was
used to identify the types of molecular pathways most overrepresented in the gene lists of the ZMIZ1
molecular phenotype (Fig. 2). Specifically, GeneGo Maps, GeneGo Map folders, GeneGo Networks,
Gene Ontology processes, and Gene Ontology molecular functions over-represented are shown in
Figs. 2A–E respectively. The flow cytometry gating strategy to identify the immune cell subsets
expressing ZMIZ1 and RPS6 is described in Figs. 3A and B respectively. A list of MS risk single
nucleotide polymorphisms (SNPs) tested for association with gene expression in whole blood in this
study is presented in Table 2.2. Experimental design, materials and methods
2.1. Cohorts
Untreated MS patients who had not been on immunomodulatory therapies for at least three
months and age-matched healthy controls were recruited for the following cohorts. The molecular
phenotypes were determined from previously described transcriptomic cohorts (all PAXgene whole
blood samples): ANZgene (2010) [2]; clinically isolated syndrome (CIS; or first clinical diagnosis of
central nervous system demyelination) [3] and RNAseq [4,5]. All MS patients were diagnosed using
the revised MacDonald criteria [6]. All blood was collected with informed consent after the nature
and possible consequences of the studies were explained from people with MS and healthy controls
with approval from Human Research Ethics Committees.
2.2. Molecular phenotypes
The genes most correlated with ZMIZ1, ZFP36L2 and RPS6 expression in PAXgene whole blood was
determined by Pearson's correlation using an RNAseq dataset of MS patients and healthy controls [4].
To visualise relative expression levels across different immune cell populations for the most corre-
lated genes, a heatmap was generated using an RNAseq dataset of ex-vivo and in-vitro differentiated
immune cell subsets, as previously described [7]. These genes were assessed for immune cell tran-
scription factor roles and involvement in molecular pathways using GeneGo Metacore. Genes
Fig. 1. Relative expression in immune cell subsets of ZMIZ1 and the 50 genes whose expression is most highly negatively
correlated with ZMIZ1 expression in PAXgene whole blood in multiple sclerosis and healthy controls. (These were determined
in the RNASeq cohort: n¼32 MS, n¼40 healthy controls, [4]. These genes are mostly expressed in lymphocytes. Expression was
by RNASeq and colour on heatmap indicates relative expression level: orange is high, blue is low. Cell subsets were ex vivo or
in-vitro generated as previously described [7]. Pearson's correlation (R) of expression with ZFP36L2 and RPS6 is also shown for
each module gene, red is positive correlation and green is negative correlation. ZFP36L2 correlations all less than r¼-0.27
(p¼0.02), RPS6 correlations all greater than r¼0.54 (p¼8.9E-07). (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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Fig. 2. Gene pathways, diseases, process networks, processes, and molecular functions enriched for the ZMIZ1 Molecular Module
genes (the 200 genes with expression most highly positively correlated with ZMIZ1 gene expression in whole blood). The 20 most
over-represented items in the module are shown for A. Pathway maps; B. Pathway map folders (diseases); C. Process networks; D.
Processes; E. Molecular functions. Enrichment analysis using Gene Ontology (GO) software (http://geneontology.org/); with items
listed in order of significance; p value shows the probability that the module is not over-represented; FDR: false discovery rate;
ratio is the number of genes from the ZMIZ1 module in the pathway, compared to the total number of genes in the pathway.
N. Fewings et al. / Data in Brief 11 (2017) 364–370368associated with MS were also noted. We then tested correlations in previously described cohorts used
for transcriptomic studies: the ANZgene microarray cohort [2], and the CIS cohort [3].
2.3. Flow cytometry
Venous blood was collected in EDTA and peripheral blood mononuclear cells (PBMCs) isolated on
Ficoll-Paque Plus (VWR International), washed in phosphate-buffered saline (PBS) and cryopreserved
in RPMI 1640 Medium (Life Technologies) containing 2 mM glutamine, 10% heat-inactivated fetal
bovine serum (FBS, Fisher Biotec), 10% DMSO and 50 units/ml penicillin and 50 mg/ml streptomycin.
PBMCs were thawed, washed in RPMI with 2% FBS, and incubated for 30 min in RPMI with 2% FBS,
10 mM HEPES, 1 mM magnesium chloride and 100 units/ml DNase I (Roche). Cells were stained with
Live/Dead Aqua viability stain (Molecular Probes) in PBS on ice for 30 min, washed in PBS, and
blocked with 33 mg/ml mouse IgG (Life technologies). Antibodies were as described in [1].
Table 2
List of MS risk SNPs tested for association with gene expression in whole blood in
this study.
Gene SNP Reference
RPS6KB1 rs180515 [9]
ZMIZ1 rs1782645 [10]
ZFP36L2 rs2163226 [9]
HLADRB1 rs2516049 [10]
CYP27B1 rs10877012 [11]
CYP24A1 rs2248359 [10]
Fig. 3. Flow cytometric gating of PBMC subsets for determination of ZMIZ1 and RPS6 protein expression. (A) ZMIZ1 panel:
progressive gating of subsets of interest, and ZMIZ1 median fluorescence intensity of DC and monocyte subsets relative to
isotype control; (B) RPS6 panel: gating of live PBMCs and their median fluorescence intensity of RPS6 relative to isotype
control.
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